Halaven is owned by Eisai Inc.
Halaven contains Eribulin Mesylate.
Halaven has a total of 4 drug patents out of which 0 drug patents have expired.
Halaven was authorised for market use on 15 November, 2010.
Halaven is available in solution;intravenous dosage forms.
The generics of Halaven are possible to be released after 08 July, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US6214865||EISAI INC||Macrocyclic analogs and methods of their use and preparation|| |
(5 months from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|EISAI INC||Macrocyclic analogs and methods of their use and preparation|| |
(11 months from now)
|USRE46965||EISAI INC||Intermediates for the preparation of analogs of Halichondrin B|| |
(3 years from now)
|EISAI INC||Intermediates for the preparation of analogs of Halichondrin B|| |
(4 years from now)
|Orphan Drug Exclusivity (ODE)||Jan 28, 2023|
|M||Sep 13, 2025|
|Pediatric Exclusivity (PED)||Mar 13, 2026|
Market Authorisation Date: 15 November, 2010
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic